Teva Appoints New President and CEO of Generics Group
Teva Pharmaceutical Industries has named Dipankar Bhattacharjee president and chief executive officer (CEO), Global Generic Medicines Group, effective on December 5, 2016. He succeeds Sigurdur Olafsson, who will step down from his role and remain active with the company until officially retiring at the end of the first quarter of 2017.
Mr. Bhattacharjee has served as president and CEO of Teva Generics Europe since April 2013. He will now be based in the US. As president and CEO of Teva Generics Europe, Mr. Bhattacharjee has a record of improving revenues and profitability, increasing operating profit margins in the European generics business. Under his leadership, Teva’s European business demonstrated consistent improvement in sales and profits. He led a full European integration of Actavis Generics and oversaw new product launches.
Mr. Bhattacharjee joined Teva as general manager, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including vice president commercial in both Europe and Asia-Pacific regions and corporate vice president and president, Asia Pacific-Region. He began his career at Nestle S.A. and Bank of America.
Source: Teva Pharmaceutical Industries